HCW Biologics Inc. (HCWB)
0.7352
-0.03
(-3.76%)
USD |
NASDAQ |
Nov 19, 11:07
HCW Biologics Enterprise Value : 7.585M for Nov. 18, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 18, 2026 | 7.585M |
| November 17, 2026 | 7.613M |
| November 16, 2026 | 7.665M |
| November 13, 2026 | 7.605M |
| November 12, 2026 | 7.667M |
| November 11, 2026 | 7.800M |
| November 10, 2026 | 7.978M |
| November 09, 2026 | 8.010M |
| November 06, 2026 | 8.157M |
| November 05, 2026 | 8.202M |
| November 04, 2026 | 8.292M |
| November 03, 2026 | 8.448M |
| November 02, 2026 | 8.381M |
| October 30, 2026 | 8.336M |
| October 29, 2026 | 8.515M |
| October 28, 2026 | 8.605M |
| October 27, 2026 | 8.426M |
| October 26, 2026 | 8.336M |
| October 23, 2026 | 8.493M |
| October 22, 2026 | 8.381M |
| October 21, 2026 | 8.470M |
| October 20, 2026 | 8.493M |
| October 19, 2026 | 8.627M |
| October 16, 2026 | 8.649M |
| October 15, 2026 | 8.627M |
| Date | Value |
|---|---|
| October 14, 2026 | 8.493M |
| October 13, 2026 | 8.694M |
| October 12, 2026 | 9.186M |
| October 09, 2026 | 9.454M |
| October 08, 2026 | 9.298M |
| October 07, 2026 | 9.365M |
| October 06, 2026 | 9.387M |
| October 05, 2026 | 9.544M |
| October 02, 2026 | 9.633M |
| October 01, 2026 | 9.656M |
| September 30, 2026 | 9.700M |
| September 29, 2026 | 8.651M |
| September 28, 2026 | 8.764M |
| September 25, 2026 | 8.942M |
| September 24, 2026 | 9.039M |
| September 23, 2026 | 8.505M |
| September 22, 2026 | 8.748M |
| September 21, 2026 | 8.910M |
| September 18, 2026 | 8.845M |
| September 17, 2026 | 8.974M |
| September 16, 2026 | 9.072M |
| September 15, 2026 | 9.136M |
| September 14, 2026 | 9.379M |
| September 11, 2026 | 9.444M |
| September 10, 2026 | 9.751M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Oncolytics Biotech, Inc. | 56.19M |
| Sangamo Therapeutics, Inc. | 37.32M |
| Sarepta Therapeutics, Inc. | 1.732B |
| Anixa Biosciences, Inc. | 78.76M |
| Vicapsys Life Sciences, Inc. | 16.68M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.942M |
| Revenue (Quarterly) | 0.0555M |
| Total Expenses (Quarterly) | 5.997M |
| EPS Diluted (Quarterly) | -2.827 |
| Gross Profit Margin (Quarterly) | -165.8% |
| Profit Margin (Quarterly) | -10.71K% |
| Earnings Yield | -2.61K% |
| Normalized Earnings Yield | -3183.26 |